-
Chemed Corporation (CHE) Misses Q3 EPS by 9c; reiterates guidance
-
Jefferies Upgrades Chemed (CHE) to Buy
-
Chemed Corporation (CHE) Misses Q2 EPS by $1.12, Misses on Revenue; Offers FY25 EPS Guidance
-
Jefferies Starts Chemed (CHE) at Hold
-
Chemed (CHE) PT Lowered to $640 at RBC Capital
-
Chemed Corporation (CHE) Declares $0.50 Quarterly Dividend; 0.3% Yield
-
BofA Securities on Chemed (CHE): 'attractive growth at Vitas (high single digits census) and stabilization at Roto'
-
Buy this healthcare stock following better than expected results: analyst
-
Chemed (CHE) PT Raised to $674 at RBC Capital
-
Chemed Corporation (CHE) Tops Q1 EPS by 12c, Beats on Revenue
-
Chemed (CHE) PT Raised to $667 at RBC Capital, Citing 'Continued VITAS Momentum'
-
Chemed Corporation (CHE) Tops Q4 EPS by 5c, Beats on Revenue
-
Chemed Corporation (CHE) Declares $0.50 Quarterly Dividend; 0.4% Yield
-
Chemed Corporation (CHE) Board of Directors Authorizes an Additional $300 Million
-
Chemed (CHE) PT Lowered to $633 at RBC Capital
-
Chemed Corporation (CHE) Misses Q3 EPS by 12c ; Offers Guidance
-
Chemed Corporation (CHE) Raises Quarterly Dividend 25% to $0.50; 0.3% Yield
-
Chemed Corporation (CHE) Misses Q2 EPS by 12c; raises guidance

